MEDEXUS PHARMACEUTIC.

Research MEDEXUS PHARMACEUTIC. (P731) on Bullrun: market cap EUR 96.79M. Explore financials, valuation history, model signals, and stock context.

Key Metrics

Valuation Snapshot

latest market cap is EUR 96.79M.

Five-year financial history

YearRevenueNet incomeFree cash flowGross marginDiluted EPSCashTotal debtEquity
FY2025USD 108.33MUSD 2.25MUSD 21.31M52.2%0.08USD 23.97MUSD 37.18MUSD 52.14M
FY2024USD 113.05M-USD 214.00KUSD 18.45M52.6%-0.01USD 5.26MUSD 49.90MUSD 30.32M
FY2023USD 108.10MUSD 1.22M-USD 1.81M55.5%0.06USD 13.07MUSD 70.08MUSD 22.45M
FY2022USD 76.70M-USD 2.88M-USD 8.89M49.4%-0.15USD 10.02MUSD 54.86MUSD 17.79M

Valuation history

YearSnapshot dateMarket capP/EDividend yieldAnnual dividend/share
20262026-09-15EUR 96.79Mn/an/a0

Dividend history

Latest trailing dividend snapshot: annual dividend/share 0 EUR.

About MEDEXUS PHARMACEUTIC.

Medexus Pharmaceuticals Inc. operates as a pharmaceutical company in Canada and the United States. The company focuses on various therapeutic areas comprising allergy, dermatology, hematology, oncology, rheumatology, and rare diseases. Its primary products include IXINITY, an intravenous recombinant factor IX therapeutic for use in patients with hemophilia B; Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis, psoriasis, and juvenile idiopathic arthritis;

Related stock research

Other Healthcare stocks

Frequently asked questions

What is MEDEXUS PHARMACEUTIC.'s market cap?

MEDEXUS PHARMACEUTIC.'s market capitalization is EUR 96.79M.

What does MEDEXUS PHARMACEUTIC. do?

Medexus Pharmaceuticals Inc. operates as a pharmaceutical company in Canada and the United States. The company focuses on various therapeutic areas comprising allergy, dermatology, hematology, oncology, rheumatology, and rare diseases.